Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Memphasys Ltd ( (AU:MEM) ) has shared an announcement.
Memphasys Limited announced the successful completion of a pilot study using its RoXsta™ antioxidant assay system in heifers, which demonstrated the system’s ability to reliably measure antioxidant capacity, though it did not find a significant link between antioxidant levels and pregnancy outcomes. The study highlighted the potential for RoXsta™ in cattle reproduction, particularly in bulls, and identified its promising application in early detection of mastitis in dairy cattle. A larger study with 120 bulls, funded by a multinational veterinary pharmaceutical partner, is planned to further explore these applications, indicating a strong industry interest in the technology.
More about Memphasys Ltd
Memphasys Limited is a reproductive biotechnology company focused on developing and commercializing innovative products for assisted reproduction.
Average Trading Volume: 17,373,973
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$15.94M
Find detailed analytics on MEM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue